Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models

BACKGROUND: Personalised medicine strategies may improve outcomes in pancreatic ductal adenocarcinoma (PDAC), but validation of predictive biomarkers is required. Having developed a clinical trial to assess the ATR inhibitor, AZD6738, in combination with gemcitabine (ATRi/gem), we investigated ATM l...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Cancer
Hlavní autoři: Dunlop, Charles R., Wallez, Yann, Johnson, Timothy Isaac, Bernaldo de Quirós Fernández, Sandra, Durant, Stephen T., Cadogan, Elaine B., Lau, Alan, Richards, Frances M., Jodrell, Duncan I.
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group UK 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7591912/
https://ncbi.nlm.nih.gov/pubmed/32741974
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-1016-2
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky